Murtagh J, Foerster V
Issues Emerg Health Technol. 2006 Sep(90):1-4.
(1) Liver fibrosis is associated with significant morbidity and mortality. The major cause is hepatitis C, which affects 240,000 Canadians. (2) Assessing the degree of liver fibrosis is critical to its management. Liver biopsy, an invasive procedure, is considered to be the diagnostic gold standard. (3) FibroScan is a rapid, non-invasive technology that uses low frequency vibration and ultrasound to assess the stiffness of liver tissue. (4) The diagnostic performance of FibroScan is good for identifying severe fibrosis or cirrhosis, but it is less accurate for milder presentations. (5) FibroScan is a promising technology, but large multi-centre trials comparing a range of emerging non-invasive fibrosis staging technologies are required.
（1）肝纤维化与显著的发病率和死亡率相关。主要病因是丙型肝炎，有24万加拿大人受其影响。（2）评估肝纤维化程度对其治疗至关重要。肝活检是一种侵入性操作，被认为是诊断的金标准。（3）FibroScan是一种快速、非侵入性技术，它利用低频振动和超声来评估肝组织的硬度。（4）FibroScan的诊断性能在识别严重纤维化或肝硬化方面表现良好，但对较轻病症的诊断准确性较低。（5）FibroScan是一项很有前景的技术，但需要进行大型多中心试验，以比较一系列新兴的非侵入性纤维化分期技术。
